Results from three phase 1 trials of NNC9204-1177, a glucagon/GLP-1 receptor co-agonist: Effects on weight loss and safety in adults with overweight or obesity

What Was Tested

The paper reports a study of Glucagon in the context of fat loss, obesity & body recomposition, published as a randomized controlled trial.

Glucagon/glucagon-like peptide-1 (GLP-1) receptor co-agonists may provide greater weight loss than agonists targeting the GLP-1 receptor alone.

Who Took Part

PubMed indexes the participants as adults.

How the Study Was Run

The researchers set it up as a randomized, double-blind, open-label and placebo-controlled study.

The participants were allocated by chance, so the Glucagon group and the comparison group should start out alike.

As a double-blind Glucagon study, the assignments were hidden from both participants and investigators until the end.

Everyone knew when Glucagon was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Glucagon, Hypoglycemic Agents, Obesity, Overweight, Weight Loss and Glucagon-Like Peptide-1 Receptor Agonists.

The authors tagged it with the keywords Glucose-dependent insulinotropic polypeptide and NN1177.

What This Means in Plain Language

The paper is a randomized, double-blind and open-label study of Glucagon in people with fat loss, obesity & body recomposition.

Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2023 (Molecular metabolism), a journal based in Germany.

More context: the Glucagon compound page, Fat loss, obesity & body recomposition research.